Since Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) and Cue Biopharma Inc. (NASDAQ:CUE) are part of the Biotechnology industry, they are influenced by contrast. The influences particularly affect the analyst recommendations, profitability, risk, dividends, earnings and valuation, institutional ownership of both companies.

Valuation and Earnings

In table 1 we can see Achillion Pharmaceuticals Inc. and Cue Biopharma Inc.’s gross revenue, earnings per share (EPS) and valuation.

Profitability

Table 2 shows the return on assets, return on equity and net margins of the two firms.

Liquidity

Achillion Pharmaceuticals Inc.’s Current Ratio is 19.7 while its Quick Ratio is 19.7. On the competitive side is, Cue Biopharma Inc. which has a 3 Current Ratio and a 3 Quick Ratio. Achillion Pharmaceuticals Inc. is better positioned to pay off short and long-term obligations compared to Cue Biopharma Inc.

Analyst Ratings

Achillion Pharmaceuticals Inc. and Cue Biopharma Inc. Recommendations and Ratings are available in the next table.

$5.5 is Achillion Pharmaceuticals Inc.’s average price target while its potential upside is 22.77%.

Institutional and Insider Ownership

Roughly 83% of Achillion Pharmaceuticals Inc. shares are held by institutional investors while 21.7% of Cue Biopharma Inc. are owned by institutional investors. Achillion Pharmaceuticals Inc.’s share held by insiders are 0.15%. Insiders Competitively, held 0.4% of Cue Biopharma Inc. shares.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

For the past year Achillion Pharmaceuticals Inc.’s stock price has bigger growth than Cue Biopharma Inc.

Achillion Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes small molecule drug therapies for infectious diseases and immune system disorders in the United States and internationally. Its drug candidates for treating chronic hepatitis C virus (HCV) infection comprise Odalasvir, a NS5A inhibitor, which has completed Phase IIa clinical trials; ACH-3422, a NS5B nucleotide polymerase inhibitor; and Sovaprevir, a NS3 protease inhibitor that has completed Phase II clinical trial. The company is also developing ACH-4471, a complement factor D inhibitor, which is in Phase I clinical trial to treat patients with paroxysmal nocturnal hemoglobinuria and C3G, a disease resulting from alternative pathway over-activation; and other factor D inhibitors. It has a license and development agreement with Ora, Inc. for the development and commercialization of ACH-702, a drug candidate that is delivered topically or locally; and collaboration arrangement with Janssen Pharmaceuticals Inc. to develop and commercialize antiviral drug candidates for treating HCV infection. The company was founded in 1998 and is headquartered in New Haven, Connecticut.

Cue Biopharma, Inc., a preclinical stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat various cancers and autoimmune disorders. Its lead drug candidate comprises CUE-101, a variant form of the cytokine Interleukin-2 and a T cell antigen to target and activate T cells specific to HPV-related cancers. The company's biologics drug candidates also include CUE-100 series to improve various tumor specific T cells; and CUE-200 series to reinvigorate exhausted T cells. It also offers MOD costimulatory optimization and discovery platform and viraTope T cell epitope discovery platform to develop novel biologics for addressing new indications in oncology and autoimmune disorders. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.